Zura Bio Ltd (ZURA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$4.11

From 52W high−42.90%

Volume1.95M

Market cap$387.23M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$4.11

From 52W high

−42.90%

Volume

1.95M

Market cap

$387.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.1x

P/E (TTM)

—

RSI (14)

47.2

MomentumView details →

1D Return

+0.75%

YTD Return

−24.14%

SummaryUpdated Sep 1, 2026

Zura Bio Limited (NASDAQ:ZURA) is a clinical-stage biotechnology company founded and based in San Diego, California. The company went public in March 2023 and focuses on developing novel therapeutic medicines to treat immune and inflammatory disorders. As a pre-revenue biotechnology firm, Zura Bio is currently advancing multiple drug candidates through clinical trials, with its lead programs targeting specific biological pathways involved in autoimmune and inflammatory diseases.

Ask drillr about Zura Bio Ltd →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−52.64%

ROA (TTM)

−48.05%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−57.75%

FCF YoY

−52.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−76.67%

EBITDA YoY

−45.65%

MomentumView details →

1D Return

+0.75%

YTD Return

−24.14%

1Y Return

+9.50%

RSI (14)

47.2

vs 50D SMA

−12.28%

vs 200D SMA

−23.90%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

11.29x

Quick Ratio

11.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

1.93%

Beats (12Q)

4/12

Next Q EPS Est

−$0.20

Avg Surprise (4Q)

−52.37%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−93.53M

Op. CF (TTM)

−81.60M

Next earningsMar 31, 2027 →

Latest newsMore news →

Zura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.86d ago

Similar companies

Contineum Therapeutics, Inc. Class A Common StockCTNM C4 Therapeutics, Inc.CCCC Rezolute, Inc.RZLT BlossomHill Therapeutics, Inc.BLSM Sirnaomics Ltd.02257.HK Avalo Therapeutics, Inc.AVTX Find similar companies →

Latest newsMore news →

Zura Bio Limited granted inducement stock options to purchase up to 587,000 Class A Ordinary Shares to thirteen newly hired employees on August 20, 2026, as inducements material to their employment.75d ago Zura Bio Limited announced its financial results for the second quarter ended June 30, 2026, and provided corporate updates.86d ago